Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-06-23
2010-02-02
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S411000, C548S427000, C548S455000
Reexamination Certificate
active
07655661
ABSTRACT:
Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytotoxic drugs in a targeted fashion.
REFERENCES:
patent: 5475092 (1995-12-01), Chari et al.
patent: 5585499 (1996-12-01), Chari et al.
patent: 5843937 (1998-12-01), Wang et al.
patent: 5846545 (1998-12-01), Chari et al.
patent: 6060608 (2000-05-01), Boger
patent: 6534660 (2003-03-01), Yongxin et al.
patent: 6548530 (2003-04-01), Boger
patent: 6586618 (2003-07-01), Zhao et al.
patent: 6756397 (2004-06-01), Zhao et al.
patent: 7049316 (2006-05-01), Zhao et al.
patent: 7329760 (2008-02-01), Zhao et al.
patent: 7388026 (2008-06-01), Zhao et al.
patent: 2003/0195365 (2003-10-01), Zhao et al.
patent: 03/087055 (2003-10-01), None
Ogasawara et al. Cancer Science, 2005, 85(4):418-425.(Abstract only).
Katsushige Gomi, et al., “Anticellular and Antitumor Activity of Duocarmycins, Novel Antitumor Antibiotics”, Jpn. J. Cancer Research, Jan. 1992, pp. 113-120, vol. 83.
Chong-Soon Lee, et al., “Determination of the Structural Features of (+) -CC-1065 That Are Responsible for Bending and Winding of DNA”, Chem. Res. Toxicol., 1991, pp. 203-213, vol. 4, No. 2.
David H. Swenson, et al, “Evaluation of DNA Binding Characteristics of Some CC-1065 Analogs”, Chem.-Biol. Interactions, 1988, pp. 199-213, vol. 67.
Li H. Li, et al., “Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065”, Investigational New Drugs, 1991, pp. 137-148, vol. 9, No. 2.
Bruce W. Ennis, et al., “The EGF Receptor System as a Target for Antitumor Therapy”, Cancer Investigation, 1991, pp. 553-562, vol. 9, No. 5.
Magda C. Gutowski, et al., “Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugagtes”, Cancer Res. 1991, pp. 5471- 5475, vol. 51, No. 20.
Dale L. Boger, et al., “Parallel Synthesis and Evaluation of 132 (+)-1, 2, 9, 9aTetrahydrocyclopropa[c] benz [e] indol -4 -one (CBI Anaologues of CC-1065 and the Duocarmycins Defining the Contribution of the DNA-Binding Doman),” Journal of Organic Chemistry, 2001, 66(20), 6654-6661. (abstract).
Yuqiang Wang, “Synthesis and Preliminary Biological Evaluations of CC-1065 Analogues: Effects of Different Linkers and Terminal Amides on Biological Activity”, Journal of Medicinal Chemistry (2000), 43(8), 1541-1549.
European Office Action issued Apr. 4, 2007, in EP03714044.9.
Dale L. Boger et al., “CBI Prodrug Analogs of CC-1065 and the Duocarmycins,” Synthesis, No. S.I., 1999, 1505-1509.
Alex Sparreboom et al., “Irinotecan (CPT-11) Metabolism and Disposition in Cancer Patients,” Clinical Cancer Research, 1998, 4:2747-2754.
Scot Z. Fields et al., “Phase I Study of Etoposide Phosphate (Etopophos) as a 30-Minute Infusion on Days 1, 3, and 5,” Clinical Cancer Research, 1995, 1:105-111.
Ravi V.J. Chari et al., “Enhancement of the Selectivity and Antitumor Efficacy of a CC-1065 Analogue through lmmunoconjugate Formation,” Cancer Research, 1995, 55: 4079-4084.
Chari Ravi V. J.
Zhao Robert Yongxin
ImmunoGen Inc.
Shiao Rei-tsang
Sughrue & Mion, PLLC
LandOfFree
Prodrugs of CC-1065 analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrugs of CC-1065 analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of CC-1065 analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4222295